Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

A lawsuit involving Merck's Gardasil in Los Angeles has been adjourned and will reconvene with a new jury. Read more here.

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public ...

A lawyer for the plaintiff in the case said Merck agreed to halting the trial because his team feared that extensive ...

Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus ...

Merck and a plaintiff have paused a trial over alleged injuries from the HPV vaccine Gardasil, with ties to HHS Secretary ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Recently appointed HHS Secretary Robert F. Kennedy Jr. in 2018 helped bring several cases against vaccine maker Merck, ...

Merck and a plaintiff have paused a trial over potential Gardasil injuries, with ties to Health Secretary Robert F. Kennedy Jr. The trial resumes in September. Kennedy, involved in mass litigation ...

Shares of Merck slid Tuesday in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling ...

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset better-than-expected fourth-quarter earnings.

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...